Samyang Biopharm USA Announces Hyun Jung Helen Lee, M.D., Named to PharmaVOICE 100

Samyang Biopharm USA, Inc. (https://us.samyangbiopharm.com) a global biotech subsidiary of the Samyang Biopharmaceuticals Corp. (https://samyangbiopharm.com/eng), announced today that the company’s President and CEO, Hyun Jung Helen Lee, M.D. (Helen) has been featured in the 2020 PharmaVOICE 100, a listing of the 100 Most Inspiring People in the Life Sciences Industry.

In 2005, PharmaVOICE launched the PharmaVOICE 100 as a means to celebrate the men and women throughout the life-sciences industry who provide inspiration to their peers, colleagues, and companies through their innovative and motivational approaches to addressing the industry’s myriad challenges. Now in its 15th year of publication, the PharmaVOICE 100 annually recognizes this select group of life science professionals for their positive contributions to the life sciences industry. The 2020 PharmaVOICE 100 honorees were selected from among thousands of nominees and are profiled in the publication's special July/August issue. Helen’s profile may be found here.

https://www.pharmavoice.com/article/2020-07-pharmavoice100-commanders/

“I am honored to have been selected as one of PharmaVOICE's ‘100 Most Inspiring People in Life Sciences,’” said Dr. Lee. “Being included in this group of outstanding life science leaders is both humbling and gratifying, but this individual recognition is actually a reflection of the dedication and innovation of my colleagues at Samyang Biopharm USA. It is because of their knowledge, passion and innovation that we are addressing some of the world’s most clinically relevant medical conditions today.”

Hyun Jung Helen Lee, MD, MHCM is a Gynecologist by training and has been working on the development of anti-cancer drugs for 15 years in Global, the US and Asia. Prior to joining Samyang as the CSO and CMO, she served as the Global Head of Solid Tumor Clinical Development at Shire in the US. She has held various executive positions at Baxalta, Eli Lilly and Pfizer. After graduating from Yonsei University College of Medicine, she completed her residency training at Severance Hospital, and later, earned her master's degree in Health Care Management at Harvard School of Public Health. She has also been serving as the President of Samyang Biopharm USA Inc. since October 2018.

Since becoming President and CEO of Samyang Biopharm USA, Dr. Lee has led the initiatives around two early-stage oncology collaborations with CanCure, LLC and Talix Therapeutics NV.

About Samyang Biopharm USA, Inc.

Samyang Biopharm USA, a biopharmaceutical company focused on the global development of first-in class biologic therapeutics for oncology and rare disease indications, was established as a subsidiary of Samyang Biopharmaceuticals Corporation (South Korea) in August 2018. The company collaborates with select biotechnology companies, research institutes, hospitals and universities through an “Open Innovation” strategy. Through collaborations, partnerships and in-licensing, Samyang Biopharm USA seeks to identify promising pre-clinical and early clinical candidates and advance them through clinical development with the objective of improving the lives of patients worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005333/en/